EVP, Chief Financial Officer · SAB Biotherapeutics, Inc. (SABS)

Lucy To

A named executive officer of SAB Biotherapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,831,074

Salary $475,000

FY2024: $404,431

4th of 5 named executive officers at SAB Biotherapeutics by FY2025 total.

5 named officers on file for SAB Biotherapeutics, FY2025

Lucy To’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SAB Biotherapeutics’s whole pay program stands against its peers

  • SAB Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SABS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Free

Get Lucy To’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Lucy To compensation by year

SAB Biotherapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as SAB Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$164,400$475,000
Option awards$239,300$2,147,040
Non-equity incentive—$207,572
All other$731$1,462
Total$404,431$2,831,074

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SAB Biotherapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-197607, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SAB Biotherapeutics, Inc. filed document, accession 0001193125-26-197607. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$404K
$2.8M
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option1,200,000—$2.17
Option83,334—$2.35

Per the Outstanding Equity Awards at Fiscal Year-End table in SAB Biotherapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments SAB Biotherapeutics discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control and involuntary termination$475,000$1,890,000$9,098$2,588,098
Involuntary termination without cause$475,000$1,890,000$9,098$2,588,098

Per the Potential Payments Upon Termination or Change in Control table in SAB Biotherapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

SAB Biotherapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Samuel ReichChief Executive Officer$9,434,622
Eddie SullivanPresident$6,114,100
Alexandra KropotovaEVP, Chief Medical Officer$5,126,279
Lucy To · this pageEVP, Chief Financial Officer$2,831,074
Christoph BauschEVP, Chief Operating Officer$1,682,520

The full SAB Biotherapeutics compensation record

free company brief

This page is one person within SAB Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SAB Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lucy To's compensation dossier · One-time report. No refunds.